Reata neuromuscular disorder drug meets study endpoint, stock halted
Reata Pharmaceuticals Inc.
shares surged after hours Monday as the biotech company announced positive results from a clinical trial for a neuromuscular disorder treatment. Reata shares, which had been halted after hours, surged 33% in the extended session, after closing up 5% at $100.59 in Monday trading for a market cap of just over $3 billion.
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
The 30-Second Trick to Making Garlic Extra-GarlickyThe flavor you get with this technique isn't just good—it's grate.
続きを読む »
This Expert's 30-Minute Walking Glute Workout Tones Your Butt in Ways Regular Walking Just Can'tJust walking won't work your glutes, this expert says. Instead, combine walking with bodyweight moves. Here's a 30-minute walking workout to start!
続きを読む »
UK Tech 100: The 30 most important, interesting, and impactful women shaping British technology in 2019Here are top female investors, founders, journalists, social media stars, and engineers in the UK tech sector today.
続きを読む »
Lizzie McGuire Will Return to TV as a 30-Year-Old Millennial in New YorkI must have missed this news back in August, but the upcoming Disney+ streaming service is planning to air a Lizzie McGuire reboot. I previously had no plans to get Disney+, but now that I know this, I may have to reconsider. This is how they get you.
続きを読む »